Zelluna ASA Logo

Zelluna ASA

ULTI | OL

Overview

Corporate Details

ISIN(s):
NO0010851603
LEI:
254900B4VALJZR9TL744
Country:
Norway
Address:
Ullernchausseen 64, 0379 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Zelluna ASA is a clinical-stage biopharmaceutical company focused on developing treatments for solid cancers. The company is pioneering a proprietary, allogeneic T-cell receptor-based Natural Killer (TCR-NK) cell therapy platform. This "off-the-shelf" approach merges the targeting capabilities of T-cell receptors with the therapeutic functions of NK cells to address significant unmet medical needs in oncology. Zelluna's mission is to deliver transformative, safe, and cost-efficient therapies with the potential to cure patients with advanced solid tumors.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Zelluna ASA. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-20 07:00
Investor Presentation
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General …
English 1.0 MB
2025-08-20 07:00
Investor Presentation
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General …
English 801.4 KB
2025-08-20 07:00
Earnings Release
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General …
English 5.6 KB
2025-08-14 12:00
Report Publication Announcement
Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation
English 1.7 KB
2025-07-03 12:07
Share Issue/Capital Change
Zelluna ASA - Grant of Share Options under Long-Term Incentive Program
English 3.4 KB
2025-06-25 16:19
Major Shareholding Notification
Disclosure of share transfer from Inven2 AS
English 711 bytes
2025-05-27 13:51
Major Shareholding Notification
Disclosure of Shareholding - Gjelsten Holding AS
English 1.2 KB
2025-05-27 13:38
Share Issue/Capital Change
ZLNA - New registered share capital
English 1.9 KB
2025-05-24 06:37
Share Issue/Capital Change
ZLNA - Issuance of shares through set-off of option exercise fee
English 2.3 KB
2025-05-08 05:00
Investor Presentation
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 1.3 MB
2025-05-08 05:00
Quarterly Report
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 664.4 KB
2025-05-08 05:00
Earnings Release
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 6.5 KB
2025-04-30 06:00
Report Publication Announcement
Zelluna ASA: Invitation to First Quarter 2025 results webcast presentation
English 1.7 KB
2025-04-29 12:50
Post-Annual General Meeting Information
Zelluna ASA - Annual General Meeting held on April 29, 2025
Norwegian 4.6 MB
2025-04-29 12:50
Post-Annual General Meeting Information
Zelluna ASA - Annual General Meeting held on April 29, 2025
English 1.4 KB

Automate Your Workflow. Get a real-time feed of all Zelluna ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Zelluna ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Fagron N.V. Logo
Supplies compounding ingredients and solutions for personalized medicine to healthcare professionals.
Belgium FAGR
Farmak Logo
Develops and exports a portfolio of 450+ medicines to more than 50 countries globally.
Ukraine FARM
Farmsintez ao Logo
Produces APIs & hospital drugs for oncology & specialty diseases; offers contract services.
Russian Federation LIFE
Fine Foods & Pharmaceuticals Ntm Logo
CDMO for oral solid forms for pharma, nutraceutical, cosmetic & medical device industries.
Italy FF
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Friulchem Logo Italy FCM
Fuji Pharma Co.,Ltd. Logo Japan 4554
FunPep Company Limited Logo Japan 4881
Fuso Pharmaceutical Industries,Ltd. Logo Japan 4538
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium GLPG